{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T23:36:29Z","timestamp":1792712189233,"version":"4.5.0"},"reference-count":50,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,5,15]],"date-time":"2023-05-15T00:00:00Z","timestamp":1684108800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","redjournal.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Radiation Oncology*Biology*Physics"],"published-print":{"date-parts":[[2023,11]]},"DOI":"10.1016\/j.ijrobp.2023.05.013","type":"journal-article","created":{"date-parts":[[2023,5,15]],"date-time":"2023-05-15T23:53:47Z","timestamp":1684194827000},"page":"644-651","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":20,"title":["Efficacy and Safety of Bladder Preservation Therapy in Combination with Atezolizumab and Radiation Therapy (BPT-ART) for Invasive Bladder Cancer: Interim Analysis from a Multicenter, Open-label, Prospective Phase 2 Trial"],"prefix":"10.1016","volume":"117","author":[{"given":"Tomokazu","family":"Kimura","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hitoshi","family":"Ishikawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshiyuki","family":"Nagumo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuta","family":"Sekino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yukio","family":"Kageyama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroki","family":"Ushijima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Taketo","family":"Kawai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hideomi","family":"Yamashita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haruhito","family":"Azuma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keiji","family":"Nihei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masae","family":"Takemura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koichi","family":"Hashimoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazushi","family":"Maruo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toyonori","family":"Tsuzuki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroyuki","family":"Nishiyama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ijrobp.2023.05.013_bib0001","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1016\/j.eururo.2003.10.006","article-title":"Prognosis of muscle-invasive bladder cancer: Difference between primary and progressive tumours and implications for therapy","volume":"45","author":"Schrier","year":"2004","journal-title":"Eur Urol"},{"key":"10.1016\/j.ijrobp.2023.05.013_bib0002","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1016\/j.eururo.2020.03.055","article-title":"European Association of Urology guidelines on muscle-invasive and metastatic bladder cancer: Summary of the 2020 guidelines","volume":"79","author":"Witjes","year":"2021","journal-title":"Eur Urol"},{"key":"10.1016\/j.ijrobp.2023.05.013_bib0003","doi-asserted-by":"crossref","first-page":"866","DOI":"10.6004\/jnccn.2022.0041","article-title":"NCCN Guidelines\u00ae Insights: Bladder Cancer, Version 2.2022","volume":"20","author":"Flaig","year":"2022","journal-title":"J Natl Compr Canc Netw"},{"key":"10.1016\/j.ijrobp.2023.05.013_bib0004","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1016\/j.annonc.2021.11.012","article-title":"Bladder cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up","volume":"33","author":"Powles","year":"2022","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ijrobp.2023.05.013_bib0005","series-title":"Bladder cancer: Diagnosis and management, NICE guideline","year":"2015"},{"key":"10.1016\/j.ijrobp.2023.05.013_bib0006","doi-asserted-by":"crossref","first-page":"4912","DOI":"10.1200\/JCO.2010.28.4950","article-title":"Radiotherapy with concurrent carbogen and nicotinamide in bladder carcinoma","volume":"28","author":"Hoskin","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ijrobp.2023.05.013_bib0007","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1093\/jjco\/hyw151","article-title":"Long-term single-institute experience with trimodal bladder-preserving therapy with proton beam therapy for muscle-invasive bladder cancer","volume":"47","author":"Takaoka","year":"2017","journal-title":"Jpn J Clin Oncol"},{"key":"10.1016\/j.ijrobp.2023.05.013_bib0008","doi-asserted-by":"crossref","first-page":"e457","DOI":"10.1016\/j.ijrobp.2011.05.051","article-title":"Whole-pelvis or bladder-only chemoradiation for lymph node-negative invasive bladder cancer: Single-institution experience","volume":"82","author":"Tunio","year":"2012","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ijrobp.2023.05.013_bib0009","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1016\/j.eururo.2011.11.010","article-title":"Long-term outcomes of selective bladder preservation by combined-modality therapy for invasive bladder cancer: The MGH experience","volume":"61","author":"Efstathiou","year":"2012","journal-title":"Eur Urol"},{"key":"10.1016\/j.ijrobp.2023.05.013_bib0010","doi-asserted-by":"crossref","first-page":"1477","DOI":"10.1056\/NEJMoa1106106","article-title":"Radiotherapy with or without chemotherapy in muscle-invasive bladder cancer","volume":"366","author":"James","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ijrobp.2023.05.013_bib0011","doi-asserted-by":"crossref","first-page":"1276","DOI":"10.1097\/01.ju.0000140456.42509.b6","article-title":"Effective bladder sparing therapy with intra-arterial cisplatin and radiotherapy for localized bladder cancer","volume":"172","author":"Eapen","year":"2004","journal-title":"J Urol"},{"key":"10.1016\/j.ijrobp.2023.05.013_bib0012","doi-asserted-by":"crossref","first-page":"2106","DOI":"10.1038\/sj.bjc.6601852","article-title":"Long-term results of a phase II study of synchronous chemoradiotherapy in advanced muscle invasive bladder cancer","volume":"90","author":"Hussain","year":"2004","journal-title":"Br J Cancer"},{"key":"10.1016\/j.ijrobp.2023.05.013_bib0013","doi-asserted-by":"crossref","first-page":"952","DOI":"10.1016\/j.eururo.2016.12.020","article-title":"Long-term outcomes after bladder-preserving tri-modality therapy for patients with muscle-invasive bladder cancer: An updated analysis of the Massachusetts General Hospital experience","volume":"71","author":"Giacalone","year":"2017","journal-title":"Eur Urol"},{"key":"10.1016\/j.ijrobp.2023.05.013_bib0014","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1016\/S1470-2045(21)00004-8","article-title":"Adjuvant atezolizumab versus observation in muscle-invasive urothelial carcinoma (IMvigor010): A multicentre, open-label, randomised, phase 3 trial","volume":"22","author":"Bellmunt","year":"2021","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ijrobp.2023.05.013_bib0015","doi-asserted-by":"crossref","first-page":"3353","DOI":"10.1200\/JCO.18.01148","article-title":"Pembrolizumab as neoadjuvant therapy before radical cystectomy in patients with muscle-invasive urothelial bladder carcinoma (PURE-01): An open-label, single-arm, phase II study","volume":"36","author":"Necchi","year":"2018","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ijrobp.2023.05.013_bib0016","doi-asserted-by":"crossref","first-page":"1218","DOI":"10.1056\/NEJMoa2002788","article-title":"Avelumab maintenance therapy for advanced or metastatic urothelial carcinoma","volume":"383","author":"Powles","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ijrobp.2023.05.013_bib0017","doi-asserted-by":"crossref","first-page":"1909","DOI":"10.1016\/S0140-6736(16)00561-4","article-title":"Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: A single-arm, multicentre, phase 2 trial","volume":"387","author":"Rosenberg","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.ijrobp.2023.05.013_bib0018","doi-asserted-by":"crossref","first-page":"1483","DOI":"10.1016\/S1470-2045(17)30616-2","article-title":"First-line pembrolizumab in cisplatin-ineligible patients with locally advanced and unresectable or metastatic urothelial cancer (KEYNOTE-052): A multicentre, single-arm, phase 2 study","volume":"18","author":"Balar","year":"2017","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ijrobp.2023.05.013_bib0019","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.1056\/NEJMoa1613683","article-title":"Pembrolizumab as second-line therapy for advanced urothelial carcinoma","volume":"376","author":"Bellmunt","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ijrobp.2023.05.013_bib0020","doi-asserted-by":"crossref","first-page":"2102","DOI":"10.1056\/NEJMoa2034442","article-title":"Adjuvant nivolumab versus placebo in muscle-invasive urothelial carcinoma","volume":"384","author":"Bajorin","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ijrobp.2023.05.013_bib0021","doi-asserted-by":"crossref","first-page":"1706","DOI":"10.1038\/s41591-019-0628-7","article-title":"Clinical efficacy and biomarker analysis of neoadjuvant atezolizumab in operable urothelial carcinoma in the ABACUS trial","volume":"25","author":"Powles","year":"2019","journal-title":"Nat Med"},{"key":"10.1016\/j.ijrobp.2023.05.013_bib0022","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1056\/NEJMoa1112824","article-title":"Immunologic correlates of the abscopal effect in a patient with melanoma","volume":"366","author":"Postow","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ijrobp.2023.05.013_bib0023","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1186\/s13045-018-0647-8","article-title":"Abscopal effect of radiotherapy combined with immune checkpoint inhibitors","volume":"11","author":"Liu","year":"2018","journal-title":"J Hematol Oncol"},{"key":"10.1016\/j.ijrobp.2023.05.013_bib0024","doi-asserted-by":"crossref","first-page":"38","DOI":"10.3390\/cancers14010038","article-title":"Bladder-sparing chemoradiotherapy combined with immune checkpoint inhibition for locally advanced urothelial bladder cancer\u2014A review","volume":"14","author":"van Hattum","year":"2022","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.ijrobp.2023.05.013_bib0025","doi-asserted-by":"crossref","DOI":"10.1016\/j.conctc.2021.100724","article-title":"Bladder preservation therapy in combination with atezolizumab and radiation therapy for invasive bladder cancer (BPT-ART) \u2013 A study protocol for an open-label, phase II, multicenter study","volume":"21","author":"Sekino","year":"2021","journal-title":"Contemp Clin Trials Commun"},{"key":"10.1016\/j.ijrobp.2023.05.013_bib0026","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/S0936-6555(05)80838-6","article-title":"Clinical Oncology original article bladder cancer: Long-term follow-up results of patients treated with radical radiation","volume":"3","author":"Gospodarowicz","year":"1991","journal-title":"Clin Oncol"},{"key":"10.1016\/j.ijrobp.2023.05.013_bib0027","doi-asserted-by":"crossref","first-page":"3036","DOI":"10.1002\/1097-0142(19931115)72:10<3036::AID-CNCR2820721028>3.0.CO;2-B","article-title":"Bladder cancer definitive radiation therapy of muscle-invasive bladder cancer: A retrospective analysis of 317 patients","volume":"72","author":"Fossi","year":"1993","journal-title":"Cancer"},{"key":"10.1016\/j.ijrobp.2023.05.013_bib0028","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1053\/clon.2002.0055","article-title":"Radical radiotherapy and salvage cystectomy as the primary management of transitional cell carcinoma of the bladder: Results following the introduction of a CT planning technique","volume":"14","author":"Borgaonkar","year":"2002","journal-title":"Clin Oncol"},{"key":"10.1016\/j.ijrobp.2023.05.013_bib0029","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1016\/0360-3016(94)90004-3","article-title":"Muscle-invasive bladder cancer treated with external beam radiotherapy: Prognostic factors","volume":"30","author":"Pollack","year":"1994","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ijrobp.2023.05.013_bib0030","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1093\/jjco\/hyp023","article-title":"Bladder preservation therapy conducted by intra-arterial chemotherapy and radiotherapy for muscle invasive bladder cancer","volume":"39","author":"Hashine","year":"2009","journal-title":"Jpn J Clin Oncol"},{"key":"10.1016\/j.ijrobp.2023.05.013_bib0031","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.radonc.2006.09.001","article-title":"Efficacy and tolerability of concurrent weekly low dose cisplatin during radiation treatment of localised muscle invasive bladder transitional cell carcinoma: A report of two sequential phase II studies from the Trans-Tasman Radiation Oncology Group","volume":"81","author":"Gogna","year":"2006","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.ijrobp.2023.05.013_bib0032","doi-asserted-by":"crossref","first-page":"1056","DOI":"10.1016\/j.urology.2012.07.045","article-title":"Long-term results of two prospective bladder-sparing trimodality approaches for invasive bladder cancer: Neoadjuvant chemotherapy and concurrent radio-chemotherapy","volume":"80","author":"Zapatero","year":"2012","journal-title":"Urology"},{"key":"10.1016\/j.ijrobp.2023.05.013_bib0033","doi-asserted-by":"crossref","first-page":"852","DOI":"10.1093\/jjco\/hym129","article-title":"Background variables for the patients with invasive bladder cancer suitable for bladder-preserving therapy","volume":"37","author":"Miyanaga","year":"2007","journal-title":"Jpn J Clin Oncol"},{"key":"10.1016\/j.ijrobp.2023.05.013_bib0034","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/j.urolonc.2008.07.005","article-title":"Combined modality treatment with bladder preservation for muscle invasive bladder cancer","volume":"28","author":"Sabaa","year":"2010","journal-title":"Urol Oncol"},{"key":"10.1016\/j.ijrobp.2023.05.013_bib0035","doi-asserted-by":"crossref","first-page":"1839","DOI":"10.1038\/s41591-020-1085-z","article-title":"Preoperative ipilimumab plus nivolumab in locoregionally advanced urothelial cancer: The NABUCCO trial","volume":"26","author":"van Dijk","year":"2020","journal-title":"Nat Med"},{"key":"10.1016\/j.ijrobp.2023.05.013_bib0036","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1038\/nrclinonc.2016.211","article-title":"Radiotherapy and immunotherapy: A beneficial liaison?","volume":"14","author":"Weichselbaum","year":"2017","journal-title":"Nat Rev Clin Oncol"},{"key":"10.1016\/j.ijrobp.2023.05.013_bib50","doi-asserted-by":"crossref","first-page":"1168","DOI":"10.1016\/j.ijrobp.2018.04.070","article-title":"Dose-limiting urinary toxicity with pembrolizumab combined with weekly hypofractionated radiation therapy in bladder cancer","volume":"101","author":"Tree","year":"2018","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ijrobp.2023.05.013_bib0037","doi-asserted-by":"crossref","first-page":"786.e1","DOI":"10.1016\/j.urolonc.2021.03.009","article-title":"Systematic review and meta-analysis of radiation therapy for high-risk non-muscle invasive bladder cancer","volume":"39","author":"Rodrigues Pessoa","year":"2021","journal-title":"Urol Oncol"},{"key":"10.1016\/j.ijrobp.2023.05.013_bib0038","doi-asserted-by":"crossref","first-page":"5536","DOI":"10.1200\/JCO.2006.07.6729","article-title":"Trimodality treatment and selective organ preservation for bladder cancer","volume":"24","author":"R\u00f6del","year":"2006","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ijrobp.2023.05.013_bib0039","doi-asserted-by":"crossref","first-page":"3801","DOI":"10.1200\/JCO.2014.57.5548","article-title":"Long-term outcomes in patients with muscle-invasive bladder cancer after selective bladder-preserving combined-modality therapy: A pooled analysis of radiation therapy oncology group protocols 8802, 8903, 9506, 9706, 9906, and 0233","volume":"32","author":"Mak","year":"2014","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ijrobp.2023.05.013_bib0040","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1016\/j.eururo.2014.02.038","article-title":"Critical analysis of bladder sparing with trimodal therapy in muscle-invasive bladder cancer: A systematic review","volume":"66","author":"Ploussard","year":"2014","journal-title":"Eur Urol"},{"key":"10.1016\/j.ijrobp.2023.05.013_bib0041","doi-asserted-by":"crossref","first-page":"3021","DOI":"10.1158\/1078-0432.CCR-22-0413","article-title":"Pembrolizumab in combination with neoadjuvant chemoradiotherapy for patients with resectable adenocarcinoma of the gastroesophageal junction","volume":"28","author":"Zhu","year":"2022","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ijrobp.2023.05.013_bib0042","doi-asserted-by":"crossref","first-page":"2148","DOI":"10.1002\/cncr.34176","article-title":"Durvalumab and tremelimumab with definitive chemoradiotherapy for locally advanced esophageal squamous cell carcinoma","volume":"128","author":"Park","year":"2022","journal-title":"Cancer"},{"key":"10.1016\/j.ijrobp.2023.05.013_bib0043","first-page":"90","article-title":"PD-1 and PD-L1 expression predict regression and prognosis following neoadjuvant radiochemotherapy of oesophageal adenocarcinoma","volume":"34","author":"G\u00f6bel","year":"2022","journal-title":"Clin Transl Radiat Oncol"},{"key":"10.1016\/j.ijrobp.2023.05.013_bib0044","doi-asserted-by":"crossref","first-page":"2342","DOI":"10.1056\/NEJMoa1809697","article-title":"Overall survival with durvalumab after chemoradiotherapy in stage III NSCLC","volume":"379","author":"Antonia","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ijrobp.2023.05.013_bib0045","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1016\/j.ejca.2020.08.028","article-title":"Impact of chemoradiotherapy on the immune-related tumour microenvironment and efficacy of anti-PD-(L)1 therapy for recurrences after chemoradiotherapy in patients with unresectable locally advanced non-small cell lung cancer","volume":"140","author":"Shirasawa","year":"2020","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.ijrobp.2023.05.013_bib0046","doi-asserted-by":"crossref","first-page":"19740","DOI":"10.1038\/srep19740","article-title":"The role of PD-L1 in the radiation response and clinical outcome for bladder cancer","volume":"6","author":"Wu","year":"2016","journal-title":"Sci Rep"},{"key":"10.1016\/j.ijrobp.2023.05.013_bib0047","doi-asserted-by":"crossref","first-page":"7913","DOI":"10.18632\/oncotarget.6861","article-title":"The role of PD-L1 in the radiation response and prognosis for esophageal squamous cell carcinoma related to IL-6 and T-cell immunosuppression","volume":"7","author":"Chen","year":"2016","journal-title":"Oncotarget"},{"key":"10.1016\/j.ijrobp.2023.05.013_bib0048","doi-asserted-by":"crossref","first-page":"738","DOI":"10.1016\/j.ijrobp.2020.12.033","article-title":"Phase 1 trial of atezolizumab plus trimodal therapy in patients with localized muscle-invasive bladder cancer","volume":"110","author":"Marcq","year":"2021","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ijrobp.2023.05.013_bib0049","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/S0140-6736(16)32455-2","article-title":"Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: A single-arm, multicentre, phase 2 trial","volume":"389","author":"Balar","year":"2017","journal-title":"Lancet"}],"container-title":["International Journal of Radiation Oncology*Biology*Physics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0360301623004613?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0360301623004613?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,6]],"date-time":"2025-10-06T10:07:47Z","timestamp":1759745267000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0360301623004613"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,11]]},"references-count":50,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2023,11]]}},"alternative-id":["S0360301623004613"],"URL":"https:\/\/doi.org\/10.1016\/j.ijrobp.2023.05.013","relation":{},"ISSN":["0360-3016"],"issn-type":[{"value":"0360-3016","type":"print"}],"subject":[],"published":{"date-parts":[[2023,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Efficacy and Safety of Bladder Preservation Therapy in Combination with Atezolizumab and Radiation Therapy (BPT-ART) for Invasive Bladder Cancer: Interim Analysis from a Multicenter, Open-label, Prospective Phase 2 Trial","name":"articletitle","label":"Article Title"},{"value":"International Journal of Radiation Oncology*Biology*Physics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ijrobp.2023.05.013","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The Author(s). Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}